Phase I/IIa Study of FIXFc in Hemophilia B Patients

Completed · Phase 1

Conditions studied: Hemophilia B

In brief

The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.

Key facts

Study ID

NCT00716716

Run by

Bioverativ Therapeutics Inc.

People needed

10

Starts

2008-04-01

Expected to finish

2009-10-01

Last updated by the study team

2020-12-19

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• RUSH University Medical Center — Chicago, Illinois, United States
• Indiana Hemophilia & Thrombosis Center — Indianapolis, Indiana, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• University of North Carolina Medical School — Chapel Hill, North Carolina, United States
• Hemophilia Center of Western PA — Pittsburgh, Pennsylvania, United States
• Puget Sound Blood Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.